Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828769 | 0.80 | F10 (0.51) | F10ATML3MBTL1 | |
| SCHEMBL4848578 | 0.79 | F10 (0.49) | F10ATML3MBTL1KLKB1 | |
| SCHEMBL3829897 | 0.79 | F10 (0.50) | F10ATML3MBTL1KLKB1 | |
| SCHEMBL3833838 | 0.78 | F10 (0.70) | F10KLKB1 | |
| SCHEMBL3832110 | 0.77 | F10 (0.60) | F10 | |
| SCHEMBL3835389 | 0.77 | F10 (0.60) | F10 | |
| SCHEMBL3828590 | 0.77 | F10 (0.67) | F10 | |
| SCHEMBL4110651 | 0.77 | F10 (0.70) | F10KLKB1 | |
| SCHEMBL5724568 | 0.76 | F10 (0.68) | F10KLKB1 | |
| SCHEMBL3829947 | 0.76 | F10 (0.59) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | claimed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | claimed |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | PFIZER INC | 2009-09-03 | — | — | US | disclosed |
| EP-2085391-A2 | Inhibitors of factor XA and other serine proteases involved in the coagulation cascade | Warner-Lambert Company LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | WARNER-LAMBERT COMPANY LLC | 2008-11-20 | — | — | US | disclosed |
| US-7407974-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1671949-A2 | Substituted phenylamines and pyridinylamines | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | disclosed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | TFPI, F11, F2 | F10 11/4885ATM 1254/4885L3MBTL1 842/4885 |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | F10 10/4885ATM 1449/4885L3MBTL1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.